Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415961 | 0.96 | CHUK (0.39) | CHUKPDE10AADORA2AADORA1ADORA3 | |
| SCHEMBL2415857 | 0.89 | PDE10A (0.38) | CHUKPDE10AADORA2AADORA1ADORA3 | |
| SCHEMBL2411529 | 0.89 | SMPD3 (0.33) | — | |
| SCHEMBL2413886 | 0.86 | PDE10A (0.34) | CHUKPDE10A | |
| SCHEMBL2415739 | 0.85 | ADORA2A (0.38) | CHUKPDE10AADORA2AADORA1ADORA3 | |
| SCHEMBL2412675 | 0.85 | CHUK (0.47) | CHUKPDE10AADORA2AADORA1ADORA3 | |
| SCHEMBL2412474 | 0.83 | ALDH1A1 (0.36) | — | |
| SCHEMBL2415012 | 0.83 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL2416331 | 0.81 | MAP4K4 (0.43) | PDE10A | |
| SCHEMBL2411521 | 0.81 | MAPT (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1312606-B1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | OREAL (FR) | 2011-09-21 | — | — | EP | claimed |
| US-6837908-B2 | 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2005-01-04 | — | — | US | claimed |
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2003-09-04 | — | — | US | claimed |
| EP-1312606-A1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | L'OREAL (FR) | 2003-05-21 | — | — | EP | claimed |
| EP-1312606-B1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | OREAL (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-6837908-B2 | 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | L'OREAL S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| EP-1312606-A1 | 2,5-diaminopyridine oxidation bases and their use for dyeing of keratin fibres | L'OREAL (FR) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030163876-A1 | Novel 2,5-diaminopyridine oxidation bases for the dyeing of keratin fibres | KRT18, DPYD, DSP | CHUK 4002/4885PDE10A 3263/4885ADORA2A 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.